Evidence map›Paper›PMID 42745975›Full record

ArticleFrontiers in immunology2026

Eric G Hernández, Diego A Daza-Mendoza, Enrique González-Rivas, Angélica Serrano-Vázquez, Horacio Pérez-Juárez, Alina Uribe-García, Gareth O Rostro-Alonso, Patricia Morán-Silva, Liliana Rojas-Velázquez, Cecilia Ximénez García

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eric G HernándezLaboratorio de Inmunología, Unidad de Medicina Experimental "Doctor Ruy Pérez-Tamayo", Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, Mexico.
Diego A Daza-MendozaLaboratorio de Inmunología, Unidad de Medicina Experimental "Doctor Ruy Pérez-Tamayo", Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, Mexico.
Enrique González-RivasLaboratorio de Inmunología, Unidad de Medicina Experimental "Doctor Ruy Pérez-Tamayo", Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, Mexico.
Angélica Serrano-VázquezLaboratorio de Inmunología, Unidad de Medicina Experimental "Doctor Ruy Pérez-Tamayo", Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, Mexico.
Horacio Pérez-JuárezLaboratorio de Inmunología, Unidad de Medicina Experimental "Doctor Ruy Pérez-Tamayo", Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, Mexico.
Alina Uribe-GarcíaCarrera de Biología, Facultad de Estudios Superiores (FES)-Iztacala, Estado de México, Mexico.
Gareth O Rostro-AlonsoLaboratorio de Farmacogenética, Unidad Multidisciplinaria de Investigación Experimental Zaragoza (UMIEZ), Facultad de Estudios Superiores (FES)-Zaragoza, Ciudad de México, Mexico.
Patricia Morán-SilvaLaboratorio de Inmunología, Unidad de Medicina Experimental "Doctor Ruy Pérez-Tamayo", Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, Mexico.
Liliana Rojas-VelázquezLaboratorio de Inmunología, Unidad de Medicina Experimental "Doctor Ruy Pérez-Tamayo", Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, Mexico.
Cecilia Ximénez GarcíaLaboratorio de Inmunología, Unidad de Medicina Experimental "Doctor Ruy Pérez-Tamayo", Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mexico has been one of the countries most affected by the COVID-19 pandemic. Several factors can influence the susceptibility to SARS-CoV-2 infection, particularly highly polymorphic genes in the HLA system. Therefore, this pilot study analyzed the association between HLA-DRB1 genetic polymorphisms and the susceptibility and/or resistance to symptomatic SARS-CoV-2 infection in a population from the Metropolitan Area of the Valley of Mexico. Individuals with a confirmed SARS-CoV-2 infection were recruited (n = 90), as well as a seronegative control group without reported symptomatic infection (n = 60). The HLA-DRB1 locus was typed using NGS. We found a significant increase in the frequency of the

Indexed as

COVID-19HLA-DRB1 ChainsSARS-CoV-2AdultAgedAllelesFemaleGene FrequencyGenetic Predisposition to DiseaseHumansMaleMexicoMiddle AgedPilot ProjectsPolymorphism, GeneticHLA-DRB1 ChainsCOVID-19HLA-DRB1Mexican populationnext generation sequenceSARS-CoV-2 infection

Identifiers

PMID42745975
PMCPMC13574783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.